NEW BRUNSWICK, N.J.,
April 16, 2019 /PRNewswire/
-- Johnson & Johnson (NYSE: JNJ) today announced results
for first-quarter 2019. "Our strong first-quarter results reflect
continued underlying operational sales and adjusted EPS growth,"
said Alex Gorsky, Chairman and Chief
Executive Officer. "At the same time, we remain focused on
investing in innovative technologies and platforms that will make a
meaningful difference in the lives of patients around the world. I
am proud of our global colleagues' collective efforts to deliver on
our long-term goals and our ability to create value for all of our
stakeholders."
OVERALL FINANCIAL RESULTS:
|
FIRST
QUARTER
|
|
($ in Millions,
except EPS)
|
2019
|
2018
|
%
Change
|
Reported
Sales
|
$
20,021
|
$
20,009
|
0.1%
|
Net
Earnings
|
3,749
|
4,367
|
(14.2)
|
EPS
(diluted)
|
$
1.39
|
$
1.60
|
(13.1)%
|
|
|
|
|
Non-GAAP*
|
FIRST
QUARTER
|
|
($ in Millions,
except EPS)
|
2019
|
2018
|
%
Change
|
Operational
Sales
|
N/A
|
N/A
|
3.9%
|
Adjusted
Operational Sales
|
N/A
|
N/A
|
5.5
|
Adjusted Net
Earnings
|
5,661
|
5,635
|
0.5
|
Adjusted EPS
(diluted)
|
$
2.10
|
$
2.06
|
1.9%
|
* Non-GAAP
financial measure; refer to reconciliations of non-GAAP financial
measures included in accompanying schedules
|
REGIONAL SALES RESULTS:
|
FIRST
QUARTER
|
%
Change
|
($ in
Millions)
|
2019
|
2018
|
Reported
|
Operational1,2
|
Currency
|
Adjusted
Operational1,3
|
U.S.
|
$
10,129
|
$
9,951
|
1.8%
|
1.8
|
-
|
3.1
|
International
|
9,892
|
10,058
|
(1.7)
|
6.0
|
(7.7)
|
7.9
|
Worldwide
|
$
20,021
|
$
20,009
|
0.1%
|
3.9
|
(3.8)
|
5.5
|
1 Non-GAAP financial measure; refer
to reconciliations of non-GAAP financial measures included in
accompanying schedules
|
2 Excludes the impact of
translational currency
|
3 Excludes the net impact of
acquisitions and divestitures and translational currency
|
Note: values may have been
rounded
|
SEGMENT SALES RESULTS:
|
FIRST
QUARTER
|
%
Change
|
($ in
Millions)
|
2019
|
2018
|
Reported
|
Operational1,2
|
Currency
|
Adjusted
Operational1,3
|
Consumer
|
$
3,318
|
$
3,398
|
(2.4)%
|
2.2
|
(4.6)
|
0.7
|
Pharmaceuticals
|
10,244
|
9,844
|
4.1
|
7.9
|
(3.8)
|
7.9
|
Medical
Devices
|
6,459
|
6,767
|
(4.6)
|
(1.0)
|
(3.6)
|
4.3
|
Worldwide
|
$
20,021
|
$
20,009
|
0.1%
|
3.9
|
(3.8)
|
5.5
|
1 Non-GAAP financial measure; refer
to reconciliations of non-GAAP financial measures included in
accompanying schedules
|
2 Excludes the impact of
translational currency
|
3 Excludes the net impact of
acquisitions and divestitures and translational currency
|
Note:
values may have been rounded
|
SEGMENT COMMENTARY:
Consumer
Consumer worldwide operational sales,
excluding the net impact of acquisitions and divestitures grew
0.7%* driven by over-the-counter products including TYLENOL
analgesics, digestive health products and international
anti-smoking aids; and NEUTROGENA beauty products, primarily offset
by lower sales of baby care products.
Pharmaceutical
Pharmaceutical worldwide operational
sales, excluding the net impact of acquisitions and divestitures
grew 7.9%* driven by STELARA (ustekinumab), a biologic for the
treatment of a number of immune-mediated inflammatory
diseases, IMBRUVICA (ibrutinib), an oral, once-daily therapy
approved for use in treating certain B-cell malignancies, a type of
blood or lymph node cancer, DARZALEX (daratumumab), for the
treatment of multiple myeloma, TREMFYA (guselkumab), a
biologic for the treatment of adults living with moderate to severe
plaque psoriasis, INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA
(paliperidone palmitate), long-acting, injectable atypical
antipsychotics for the treatment of schizophrenia in adults,
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA (D/C/F/TAF) for the treatment
of human immunodeficiency virus type 1 (HIV-1) infection,
UPTRAVI (selexipag), an oral prostacyclin receptor agonist used to
treat pulmonary arterial hypertension and reduce hospitalization,
and ERLEADA (apalutamide), a next-generation androgen receptor
inhibitor for the treatment of patients with non-metastatic
castration-resistant prostate cancer partially offset by declines
in REMICADE (infliximab), a biologic approved for the treatment of
a number of immune-mediated inflammatory diseases, and U.S. ZYTIGA
(abiraterone acetate), an oral, once-daily medication for use in
combination with prednisone for the treatment of metastatic,
castration-resistant prostate cancer due to biosimilar and generic
entrants.
Medical Devices
Worldwide Medical Devices operational
sales, excluding the net impact of acquisitions and divestitures
grew 4.3%* driven by the growth of electrophysiology products in
the Interventional Solutions business; ACUVUE contact lenses in the
Vision business; biosurgicals in the Advanced Surgery business; and
wound closure products in the General Surgery business.
NOTABLE NEW ANNOUNCEMENTS IN THE QUARTER:
Acquisitions/Divestitures/Licenses
- Completed the divestiture of Advanced Sterilization
Products1 (press release)
- Completed the acquisition of Auris Health, Inc.1
commercially available robotic platform technology (press
release)
- Entered into an exclusive worldwide collaboration and license
agreement with MeiraGTx to develop gene therapy programs for
inherited retinal diseases (press release)
Pipeline
Updates
|
Regulatory
Approvals
|
BALVERSA
(erdafitinib) - Locally advanced or metastatic urothelial cancer
(U.S.)1
|
(press
release)
|
SPRAVATO (esketamine)
- Treatment-resistant depression (U.S.)
|
(press
release)
|
TREMFYA (guselkumab)
- One-press patient-controlled injector (U.S.)
|
(press
release)
|
DARZALEX
(daratumumab) Split-dosing regimen (U.S.)
|
(press
release)
|
IMBRUVICA (ibrutinib)
plus obinutuzumab - Chronic lymphocytic leukemia (U.S.)
|
(press
release)
|
Regulatory
Submissions
|
INVOKANA
(canagliflozin) - Chronic kidney disease in patients with Type 2
diabetes (U.S.)
|
(press
release)
|
DARZALEX
(daratumumab) - Combination therapy for transplant eligible
multiple myeloma patients (U.S.,EU)
|
(press release -
U.S.)
(press release -
EU)
|
DARZALEX
(daratumumab) - Combination therapy for transplant ineligible
multiple myeloma patients (U.S.,EU)
|
(press release -
U.S.)
(press release -
EU)
|
Other
|
Antihistamine-releasing contact lens demonstrates
positive Phase 3 results
|
(press
release)
|
ACUVUE OASYS with
TRANSITIONS LIGHT INTELLIGENT TECHNOLOGY availability
(U.S)
|
(press
release)
|
1 Subsequent to the
quarter
|
FULL YEAR 2019 GUIDANCE:
Johnson & Johnson does not provide GAAP financial measures
on a forward-looking basis because the company is unable to predict
with reasonable certainty the ultimate outcome of legal
proceedings, unusual gains and losses, acquisition-related expenses
and purchase accounting fair value adjustments without unreasonable
effort. These items are uncertain, depend on various factors, and
could be material to Johnson & Johnson's results computed in
accordance with GAAP.
|
April
2019
|
January
2019
|
($ in Billions,
except EPS)
|
|
|
Adjusted Operational
Sales1,2
Change vs. Prior
Year
|
2.5% -
3.5%
|
2.0% -
3.0%
|
Operational
Sales2
Change vs. Prior
Year
|
$82.0 to
$82.8
0.5% -
1.5%
|
$81.6 to
$82.4
0.0% -
1.0%
|
Estimated Reported
Sales3
Change vs. Prior
Year
|
$80.4 to
$81.2
(1.5%) -
(0.5%)
|
$80.4 to
$81.2
(1.5%) -
(0.5%)
|
|
|
|
Adjusted Operational
EPS (Diluted)2,4
Change vs. Prior
Year
|
$8.73 to
$8.83
6.7% -
7.9%
|
$8.65 to
$8.80
5.7% -
7.6%
|
Adjusted EPS
(Diluted)3,4
Change vs. Prior
Year
|
$8.53 to
$8.63
4.3% -
5.5%
|
$8.50 to
$8.65
3.9% -
5.8%
|
|
1 Non-GAAP financial
measure; excludes the net impact of acquisitions and
divestitures
|
2 Non-GAAP financial measure;
excludes the impact of translational currency
|
3 Calculated using Euro Average Rate:
April 2019 = $1.12; Euro Average Rate: Jan 2019 = $1.14
(Illustrative purposes only)
|
4
Non-GAAP financial measure; excludes intangible amortization
expense and special items
|
Other modeling considerations will be provided on the
webcast.
WEBCAST INFORMATION:
Johnson & Johnson will
conduct a conference call with investors to discuss this earnings
release today at 8:30 a.m., Eastern
Time. A simultaneous webcast of the call for investors and
other interested parties may be accessed by visiting the Johnson
& Johnson website. A replay and podcast will be available
approximately two hours after the live webcast in the Investors
section of the company's website at
events-and-presentations.
ABOUT JOHNSON & JOHNSON:
At Johnson & Johnson,
we believe good health is the foundation of vibrant lives, thriving
communities and forward progress. That's why for more than 130
years, we have aimed to keep people well at every age and every
stage of life. Today, as the world's largest and most broadly-based
health care company, we are committed to using our reach and size
for good. We strive to improve access and affordability, create
healthier communities, and put a healthy mind, body and environment
within reach of everyone, everywhere. We are blending our heart,
science and ingenuity to profoundly change the trajectory of health
for humanity.
NON-GAAP FINANCIAL MEASURES:
*Operational sales growth
excluding the impact of translational currency, adjusted
operational sales growth excluding the net impact of acquisitions
and divestitures and translational currency, as well as adjusted
net earnings, adjusted diluted earnings per share and adjusted
operational diluted earnings per share excluding after-tax
intangible amortization expense and special items, are non-GAAP
financial measures and should not be considered replacements for,
and should be read together with, the most comparable GAAP
financial measures. Except for guidance measures, reconciliations
of these non-GAAP financial measures to the most directly
comparable GAAP financial measures can be found in the accompanying
financial schedules of the earnings release and the Investors
section of the company's website at quarterly-results.
Copies of the financial schedules accompanying this earnings
release are available on the company's website at
quarterly-results. These schedules include supplementary sales
data, a condensed consolidated statement of earnings,
reconciliations of non-GAAP financial measures, and sales of key
products/franchises. Additional information on Johnson &
Johnson, including adjusted income before tax by segment, a
pharmaceutical pipeline of selected compounds in late stage
development and a copy of today's earnings call presentation can
also be found in the Investors section of the company's website at
quarterly-results.
NOTE TO INVESTORS CONCERNING FORWARD-LOOKING
STATEMENTS:
This press release contains "forward-looking
statements" as defined in the Private Securities Litigation Reform
Act of 1995 regarding, among other things: future operating
and financial performance, product development, market position and
business strategy. The reader is cautioned not to rely on these
forward-looking statements. These statements are based on current
expectations of future events. If underlying assumptions prove
inaccurate or known or unknown risks or uncertainties materialize,
actual results could vary materially from the expectations and
projections of Johnson & Johnson. Risks and uncertainties
include, but are not limited to: economic factors, such as interest
rate and currency exchange rate fluctuations; competition,
including technological advances, new products and patents attained
by competitors; challenges inherent in new product research and
development, including uncertainty of clinical success and
obtaining regulatory approvals; uncertainty of commercial success
for new and existing products; challenges to patents; the impact of
patent expirations; the ability of the company to successfully
execute strategic plans; the impact of business combinations and
divestitures; manufacturing difficulties or delays, internally or
within the supply chain; product efficacy or safety concerns
resulting in product recalls or regulatory action; significant
adverse litigation or government action, including related to
product liability claims; changes to applicable laws and
regulations, including tax laws and global health care reforms;
trends toward health care cost containment; changes in behavior and
spending patterns of purchasers of health care products and
services; financial instability of international economies and
legal systems and sovereign risk; increased scrutiny of the health
care industry by government agencies. A further list and
descriptions of these risks, uncertainties and other factors can be
found in Johnson & Johnson's Annual Report on Form 10-K for the
fiscal year ended December 30, 2018,
including in the sections captioned "Cautionary Note Regarding
Forward-Looking Statements" and "Item 1A. Risk Factors," and the
company's subsequent filings with the Securities and Exchange
Commission. Copies of these filings are available online at
www.sec.gov, www.jnj.com or on request from Johnson & Johnson.
Any forward-looking statement made in this release speaks only as
of the date of this release. Johnson & Johnson does not
undertake to update any forward-looking statement as a result of
new information or future events or developments.
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
Supplementary
Sales Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; Dollars
in Millions)
|
FIRST
QUARTER
|
|
|
|
|
|
Percent
Change
|
|
2019
|
|
2018
|
|
Total
|
|
Operations
|
|
Currency
|
Sales to customers
by
|
|
|
|
|
|
|
|
|
|
segment of
business
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consumer
|
|
|
|
|
|
|
|
|
|
U.S.
|
$
1,438
|
|
1,436
|
|
0.2
|
%
|
0.2
|
|
-
|
International
|
1,880
|
|
1,962
|
|
(4.2)
|
|
3.7
|
|
(7.9)
|
|
3,318
|
|
3,398
|
|
(2.4)
|
|
2.2
|
|
(4.6)
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical
|
|
|
|
|
|
|
|
|
|
U.S.
|
5,582
|
|
5,354
|
|
4.3
|
|
4.3
|
|
-
|
International
|
4,662
|
|
4,490
|
|
3.9
|
|
12.2
|
|
(8.3)
|
|
10,244
|
|
9,844
|
|
4.1
|
|
7.9
|
|
(3.8)
|
|
|
|
|
|
|
|
|
|
|
Medical
Devices
|
|
|
|
|
|
|
|
|
|
U.S.
|
3,109
|
|
3,161
|
|
(1.6)
|
|
(1.6)
|
|
-
|
International
|
3,350
|
|
3,606
|
|
(7.1)
|
|
(0.3)
|
|
(6.8)
|
|
6,459
|
|
6,767
|
|
(4.6)
|
|
(1.0)
|
|
(3.6)
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
10,129
|
|
9,951
|
|
1.8
|
|
1.8
|
|
-
|
International
|
9,892
|
|
10,058
|
|
(1.7)
|
|
6.0
|
|
(7.7)
|
Worldwide
|
$
20,021
|
|
20,009
|
|
0.1
|
%
|
3.9
|
|
(3.8)
|
|
|
|
|
|
|
|
|
|
|
Note:
Percentages have been calculated using actual, non-rounded figures
and, therefore, may not recalculate precisely.
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
Supplementary
Sales Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; Dollars
in Millions)
|
FIRST
QUARTER
|
|
|
|
|
|
Percent
Change
|
|
2019
|
|
2018
|
|
Total
|
|
Operations
|
|
Currency
|
Sales to customers
by
|
|
|
|
|
|
|
|
|
|
geographic
area
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
$
10,129
|
|
9,951
|
|
1.8
|
%
|
1.8
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Europe
|
4,609
|
|
4,797
|
|
(3.9)
|
|
4.5
|
|
(8.4)
|
Western Hemisphere
excluding U.S.
|
1,503
|
|
1,567
|
|
(4.1)
|
|
8.7
|
|
(12.8)
|
Asia-Pacific,
Africa
|
3,780
|
|
3,694
|
|
2.3
|
|
6.9
|
|
(4.6)
|
International
|
9,892
|
|
10,058
|
|
(1.7)
|
|
6.0
|
|
(7.7)
|
|
|
|
|
|
|
|
|
|
|
Worldwide
|
$
20,021
|
|
20,009
|
|
0.1
|
%
|
3.9
|
|
(3.8)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Note:
Percentages have been calculated using actual, non-rounded figures
and, therefore, may not recalculate precisely.
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
Condensed
Consolidated Statement of Earnings
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; in
Millions Except Per Share Figures)
|
FIRST
QUARTER
|
|
|
|
|
|
|
|
|
|
|
|
2019
|
|
2018
|
|
Percent
|
|
|
|
Percent
|
|
|
|
Percent
|
|
Increase
|
|
Amount
|
|
to
Sales
|
|
Amount
|
|
to
Sales
|
|
(Decrease)
|
Sales to
customers
|
$
20,021
|
|
100.0
|
|
$
20,009
|
|
100.0
|
|
0.1
|
Cost of products
sold
|
6,615
|
|
33.0
|
|
6,614
|
|
33.1
|
|
0.0
|
Gross
Profit
|
13,406
|
|
67.0
|
|
13,395
|
|
66.9
|
|
0.1
|
Selling, marketing
and administrative expenses
|
5,219
|
|
26.1
|
|
5,263
|
|
26.3
|
|
(0.8)
|
Research and
development expense
|
2,858
|
|
14.3
|
|
2,404
|
|
12.0
|
|
18.9
|
In-process
research and development
|
890
|
|
4.4
|
|
-
|
|
-
|
|
|
Interest (income)
expense, net
|
3
|
|
0.0
|
|
145
|
|
0.7
|
|
|
Other (income)
expense, net
|
(22)
|
|
(0.1)
|
|
60
|
|
0.3
|
|
|
Restructuring
|
36
|
|
0.2
|
|
42
|
|
0.2
|
|
|
Earnings before
provision for taxes on income
|
4,422
|
|
22.1
|
|
5,481
|
|
27.4
|
|
(19.3)
|
Provision for
taxes on income
|
673
|
|
3.4
|
|
1,114
|
|
5.6
|
|
(39.6)
|
Net
earnings
|
3,749
|
|
18.7
|
|
4,367
|
|
21.8
|
|
(14.2)
|
|
|
|
|
|
|
|
|
|
|
Net earnings per
share (Diluted)
|
$
1.39
|
|
|
|
$
1.60
|
|
|
|
(13.1)
|
|
|
|
|
|
|
|
|
|
|
Average shares
outstanding (Diluted)
|
2,698.8
|
|
|
|
2,731.9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective tax
rate
|
15.2
|
%
|
|
|
20.3
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted earnings
before provision for taxes and net earnings
(1)
|
|
|
|
|
|
|
|
|
|
Earnings before
provision for taxes on income
|
$
6,867
|
|
34.3
|
|
$
6,858
|
|
34.3
|
|
0.1
|
Net
earnings
|
$
5,661
|
|
28.3
|
|
$
5,635
|
|
28.2
|
|
0.5
|
Net earnings per
share (Diluted)
|
$
2.10
|
|
|
|
$
2.06
|
|
|
|
1.9
|
Effective tax
rate
|
17.6
|
%
|
|
|
17.8
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) See
Reconciliation of Non-GAAP Financial Measures.
|
|
|
|
|
|
|
|
|
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
Reconciliation of
Non-GAAP Financial Measures
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
First
Quarter
|
|
% Incr. /
|
|
|
(Dollars in
Millions Except Per Share Data)
|
|
|
2019
|
|
2018
|
|
(Decr.)
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings before
provision for taxes on income - as reported
|
|
|
$
4,422
|
|
5,481
|
|
(19.3)
|
%
|
|
Intangible asset
amortization expense
|
|
|
1,130
|
|
1,115
|
|
|
|
|
In-process research
and development
|
|
|
890
|
|
-
|
|
|
|
|
Litigation
expense
|
|
|
423
|
|
-
|
|
|
|
|
Unrealized
(gain)/loss on securities
|
|
|
(158)
|
|
27
|
|
|
|
|
Restructuring/Other
(1)
|
|
|
90
|
|
107
|
|
|
|
|
Actelion acquisition
related cost
|
|
|
39
|
|
96
|
|
|
|
|
AMO acquisition
related cost
|
|
|
28
|
|
21
|
|
|
|
|
Other
|
|
|
3
|
|
11
|
|
|
|
|
Earnings before
provision for taxes on income - as adjusted
|
|
|
$
6,867
|
|
6,858
|
|
0.1
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Net Earnings - as
reported
|
|
|
$
3,749
|
|
4,367
|
|
(14.2)
|
%
|
|
Intangible asset
amortization expense
|
|
|
846
|
|
996
|
|
|
|
|
In-process research
and development
|
|
|
703
|
|
-
|
|
|
|
|
Litigation
expense
|
|
|
342
|
|
-
|
|
|
|
|
Unrealized
(gain)/loss on securities
|
|
|
(125)
|
|
21
|
|
|
|
|
Restructuring/Other
|
|
|
75
|
|
81
|
|
|
|
|
Actelion acquisition
related cost
|
|
|
37
|
|
92
|
|
|
|
|
AMO acquisition
related cost
|
|
|
23
|
|
17
|
|
|
|
|
Impact of tax
legislation (2)
|
|
|
-
|
|
52
|
|
|
|
|
Other
|
|
|
11
|
|
9
|
|
|
|
|
Net Earnings - as
adjusted
|
|
|
$
5,661
|
|
5,635
|
|
0.5
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Diluted Net Earnings
per share - as reported
|
|
|
$
1.39
|
|
1.60
|
|
(13.1)
|
%
|
|
Intangible asset
amortization expense
|
|
|
0.31
|
|
0.36
|
|
|
|
|
In-process research
and development
|
|
|
0.26
|
|
-
|
|
|
|
|
Litigation
expense
|
|
|
0.13
|
|
-
|
|
|
|
|
Unrealized
(gain)/loss on securities
|
|
|
(0.05)
|
|
0.01
|
|
|
|
|
Restructuring/Other
|
|
|
0.03
|
|
0.03
|
|
|
|
|
Actelion acquisition
related cost
|
|
|
0.01
|
|
0.03
|
|
|
|
|
AMO acquisition
related cost
|
|
|
0.01
|
|
0.01
|
|
|
|
|
Impact of tax
legislation
|
|
|
-
|
|
0.02
|
|
|
|
|
Other
|
|
|
0.01
|
|
-
|
|
|
|
|
Diluted Net Earnings
per share - as adjusted
|
|
|
$
2.10
|
|
2.06
|
|
1.9
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Operational Diluted
Net Earnings per share - as adjusted at 2017 foreign
currency exchange rates
|
|
|
|
|
1.93
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Impact of currency at
2018 foreign currency exchange rates
|
|
|
0.08
|
|
0.13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operational Diluted
Net Earnings per share - as adjusted at 2018 foreign
currency exchange rates
|
|
|
$
2.18
|
|
2.06
|
|
5.8
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
Includes $23M recorded in cost of products sold and $31M recorded
in other (income) expense in the first quarter 2019, and $6M
recorded in cost of products sold
|
and $59M recorded in other
(income) expense in the first quarter 2018
|
|
|
|
|
|
|
|
|
|
|
(2)
Includes foreign currency translation
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
Reconciliation of
Non-GAAP Financial Measure
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
Operational Sales Growth
|
FIRST
QUARTER 2019 ACTUAL vs. 2018 ACTUAL
|
|
|
|
|
|
|
|
|
|
Segments
|
|
|
|
|
|
|
|
|
|
|
|
Consumer
|
|
Pharmaceutical
|
|
Medical
Devices
|
|
Total
|
WW As
Reported
|
|
(2.4)%
|
|
4.1%
|
|
(4.6)%
|
|
0.1%
|
U.S.
|
|
0.2%
|
|
4.3%
|
|
(1.6)%
|
|
1.8%
|
International
|
|
(4.2)%
|
|
3.9%
|
|
(7.1)%
|
|
(1.7)%
|
|
|
|
|
|
|
|
|
|
WW
Currency
|
|
(4.6)
|
|
(3.8)
|
|
(3.6)
|
|
(3.8)
|
U.S.
|
|
-
|
|
-
|
|
-
|
|
-
|
International
|
|
(7.9)
|
|
(8.3)
|
|
(6.8)
|
|
(7.7)
|
|
|
|
|
|
|
|
|
|
WW
Operational
|
|
2.2%
|
|
7.9%
|
|
(1.0)%
|
|
3.9%
|
U.S.
|
|
0.2%
|
|
4.3%
|
|
(1.6)%
|
|
1.8%
|
International
|
|
3.7%
|
|
12.2%
|
|
(0.3)%
|
|
6.0%
|
|
|
|
|
|
|
|
|
|
Beauty
|
|
|
|
|
|
|
|
|
Nizoral
|
|
0.4
|
|
|
|
|
|
0.1
|
U.S.
|
|
0.3
|
|
|
|
|
|
0.0
|
International
|
|
0.5
|
|
|
|
|
|
0.1
|
|
|
|
|
|
|
|
|
|
OTC
|
|
|
|
|
|
|
|
|
Zarbees
|
|
(0.8)
|
|
|
|
|
|
(0.1)
|
U.S.
|
|
(2.0)
|
|
|
|
|
|
(0.3)
|
International
|
|
0.0
|
|
|
|
|
|
0.0
|
|
|
|
|
|
|
|
|
|
Diabetes
Care
|
|
|
|
|
|
|
|
|
LifeScan
|
|
|
|
|
|
5.1
|
|
1.7
|
U.S.
|
|
|
|
|
|
3.8
|
|
1.2
|
International
|
|
|
|
|
|
6.2
|
|
2.3
|
|
|
|
|
|
|
|
|
|
Beauty
|
|
|
|
|
|
|
|
|
RoC
|
|
0.8
|
|
|
|
|
|
0.1
|
U.S.
|
|
1.5
|
|
|
|
|
|
0.2
|
International
|
|
0.3
|
|
|
|
|
|
0.1
|
|
|
|
|
|
|
|
|
|
Beauty
|
|
|
|
|
|
|
|
|
Dr. Ci Labo -
Japan
|
|
(2.1)
|
|
|
|
|
|
(0.4)
|
U.S.
|
|
0.0
|
|
|
|
|
|
0.0
|
International
|
|
(3.6)
|
|
|
|
|
|
(0.7)
|
|
|
|
|
|
|
|
|
|
All Other
Acquisitions and Divestitures
|
|
0.2
|
|
0.0
|
|
0.2
|
|
0.1
|
U.S.
|
|
0.0
|
|
0.0
|
|
0.3
|
|
0.1
|
International
|
|
0.4
|
|
0.0
|
|
0.0
|
|
0.1
|
|
|
|
|
|
|
|
|
|
WW Adjusted
Operational
|
|
0.7%
|
|
7.9%
|
|
4.3%
|
|
5.5%
|
U.S.
|
|
0.0%
|
|
4.3%
|
|
2.5%
|
|
3.1%
|
International
|
|
1.3%
|
|
12.2%
|
|
5.9%
|
|
7.9%
|
|
|
|
|
|
|
|
|
|
Note:
Percentages are based on actual, non-rounded figures and may not
sum
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
FIRST
QUARTER
|
|
|
|
|
|
%
Change
|
|
|
2019
|
|
2018
|
Reported
|
Operational
(1)
|
Currency
|
CONSUMER SEGMENT
(2)
|
|
|
|
|
|
|
|
BABY CARE
|
|
|
|
|
|
|
|
US
|
|
$
87
|
|
$
97
|
-10.9%
|
-10.9%
|
-
|
Intl
|
|
307
|
|
360
|
-14.8%
|
-6.4%
|
-8.4%
|
WW
|
|
394
|
|
457
|
-14.0%
|
-7.4%
|
-6.6%
|
BEAUTY
|
|
|
|
|
|
|
|
US
|
|
588
|
|
611
|
-3.8%
|
-3.8%
|
-
|
Intl
|
|
502
|
|
473
|
6.2%
|
13.1%
|
-6.9%
|
WW
|
|
1,090
|
|
1,084
|
0.6%
|
3.6%
|
-3.0%
|
ORAL CARE
|
|
|
|
|
|
|
|
US
|
|
151
|
|
157
|
-3.5%
|
-3.5%
|
-
|
Intl
|
|
216
|
|
222
|
-2.8%
|
4.6%
|
-7.4%
|
WW
|
|
367
|
|
379
|
-3.1%
|
1.2%
|
-4.3%
|
OTC
|
|
|
|
|
|
|
|
US
|
|
507
|
|
465
|
9.1%
|
9.1%
|
-
|
Intl
|
|
580
|
|
607
|
-4.6%
|
2.8%
|
-7.4%
|
WW
|
|
1,087
|
|
1,072
|
1.3%
|
5.5%
|
-4.2%
|
WOMEN'S
HEALTH
|
|
|
|
|
|
|
|
US
|
|
3
|
|
3
|
4.2%
|
4.2%
|
-
|
Intl
|
|
222
|
|
240
|
-7.5%
|
4.3%
|
-11.8%
|
WW
|
|
225
|
|
243
|
-7.3%
|
4.3%
|
-11.6%
|
WOUND CARE /
OTHER
|
|
|
|
|
|
|
|
US
|
|
102
|
|
103
|
-0.9%
|
-0.9%
|
-
|
Intl
|
|
53
|
|
60
|
-11.6%
|
-6.0%
|
-5.6%
|
WW
|
|
155
|
|
163
|
-4.8%
|
-2.7%
|
-2.1%
|
|
|
|
|
|
|
|
|
TOTAL
CONSUMER
|
|
|
|
|
|
|
|
US
|
|
1,438
|
|
1,436
|
0.2%
|
0.2%
|
-
|
Intl
|
|
1,880
|
|
1,962
|
-4.2%
|
3.7%
|
-7.9%
|
WW
|
|
$
3,318
|
|
$
3,398
|
-2.4%
|
2.2%
|
-4.6%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See footnotes at end
of schedule
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
FIRST
QUARTER
|
|
|
|
|
|
%
Change
|
|
|
2019
|
|
2018
|
Reported
|
Operational
(1)
|
Currency
|
PHARMACEUTICAL
SEGMENT (2)(4)
|
|
|
|
|
|
|
|
IMMUNOLOGY
|
|
|
|
|
|
|
|
US
|
|
$
2,163
|
|
$
2,000
|
8.1%
|
8.1%
|
-
|
Intl
|
|
1,088
|
|
1,042
|
4.5%
|
12.6%
|
-8.1%
|
WW
|
|
3,251
|
|
3,042
|
6.9%
|
9.6%
|
-2.7%
|
REMICADE
|
|
|
|
|
|
|
|
US
|
|
774
|
|
916
|
-15.5%
|
-15.5%
|
-
|
US Exports
(3)
|
|
76
|
|
142
|
-46.4%
|
-46.4%
|
-
|
Intl
|
|
252
|
|
331
|
-23.6%
|
-17.2%
|
-6.4%
|
WW
|
|
1,102
|
|
1,389
|
-20.6%
|
-19.1%
|
-1.5%
|
SIMPONI / SIMPONI
ARIA
|
|
|
|
|
|
|
|
US
|
|
263
|
|
224
|
17.0%
|
17.0%
|
-
|
Intl
|
|
261
|
|
294
|
-11.1%
|
-3.8%
|
-7.3%
|
WW
|
|
524
|
|
518
|
1.0%
|
5.2%
|
-4.2%
|
STELARA
|
|
|
|
|
|
|
|
US
|
|
882
|
|
652
|
35.2%
|
35.2%
|
-
|
Intl
|
|
523
|
|
409
|
27.9%
|
37.2%
|
-9.3%
|
WW
|
|
1,405
|
|
1,061
|
32.4%
|
36.0%
|
-3.6%
|
TREMFYA
|
|
|
|
|
|
|
|
US
|
|
168
|
|
66
|
*
|
*
|
-
|
Intl
|
|
49
|
|
6
|
*
|
*
|
*
|
WW
|
|
217
|
|
72
|
*
|
*
|
*
|
OTHER
IMMUNOLOGY(4)
|
|
|
|
|
|
|
|
US
|
|
-
|
|
-
|
-
|
-
|
-
|
Intl
|
|
3
|
|
2
|
19.5%
|
21.0%
|
-1.5%
|
WW
|
|
3
|
|
2
|
19.5%
|
21.0%
|
-1.5%
|
INFECTIOUS
DISEASES
|
|
|
|
|
|
|
|
US
|
|
357
|
|
333
|
7.3%
|
7.3%
|
-
|
Intl
|
|
489
|
|
497
|
-1.7%
|
7.8%
|
-9.5%
|
WW
|
|
846
|
|
830
|
1.9%
|
7.6%
|
-5.7%
|
EDURANT /
rilpivirine
|
|
|
|
|
|
|
|
US
|
|
12
|
|
14
|
-18.8%
|
-18.8%
|
-
|
Intl
|
|
199
|
|
196
|
2.2%
|
10.6%
|
-8.4%
|
WW
|
|
211
|
|
210
|
0.8%
|
8.6%
|
-7.8%
|
PREZISTA / PREZCOBIX
/ REZOLSTA / SYMTUZA
|
|
|
|
|
|
|
|
US
|
|
315
|
|
273
|
15.5%
|
15.5%
|
-
|
Intl
|
|
208
|
|
205
|
1.5%
|
11.9%
|
-10.4%
|
WW
|
|
523
|
|
478
|
9.5%
|
13.9%
|
-4.4%
|
OTHER INFECTIOUS
DISEASES
|
|
|
|
|
|
|
|
US
|
|
30
|
|
46
|
-33.8%
|
-33.8%
|
-
|
Intl
|
|
82
|
|
96
|
-16.0%
|
-6.3%
|
-9.7%
|
WW
|
|
112
|
|
142
|
-21.7%
|
-15.1%
|
-6.6%
|
See footnotes at end of
schedule
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
FIRST
QUARTER
|
|
|
|
|
|
%
Change
|
|
|
2019
|
|
2018
|
Reported
|
Operational
(1)
|
Currency
|
NEUROSCIENCE
|
|
|
|
|
|
|
|
US
|
|
723
|
|
624
|
16.0%
|
16.0%
|
-
|
Intl
|
|
905
|
|
935
|
-3.2%
|
4.3%
|
-7.5%
|
WW
|
|
1,629
|
|
1,559
|
4.5%
|
9.0%
|
-4.5%
|
CONCERTA /
methlyphenidate
|
|
|
|
|
|
|
|
US
|
|
97
|
|
66
|
47.7%
|
47.7%
|
-
|
Intl
|
|
116
|
|
107
|
8.5%
|
15.8%
|
-7.3%
|
WW
|
|
214
|
|
173
|
23.4%
|
28.0%
|
-4.6%
|
INVEGA SUSTENNA /
XEPLION /
INVEGA TRINZA / TREVICTA
|
|
|
|
|
|
|
|
US
|
|
483
|
|
400
|
20.7%
|
20.7%
|
-
|
Intl
|
|
307
|
|
296
|
3.8%
|
12.3%
|
-8.5%
|
WW
|
|
790
|
|
696
|
13.5%
|
17.1%
|
-3.6%
|
RISPERDAL
CONSTA
|
|
|
|
|
|
|
|
US
|
|
77
|
|
82
|
-6.8%
|
-6.8%
|
-
|
Intl
|
|
102
|
|
114
|
-10.3%
|
-2.4%
|
-7.9%
|
WW
|
|
179
|
|
196
|
-8.8%
|
-4.3%
|
-4.5%
|
OTHER
NEUROSCIENCE
|
|
|
|
|
|
|
|
US
|
|
66
|
|
76
|
-12.0%
|
-12.0%
|
-
|
Intl
|
|
379
|
|
418
|
-9.2%
|
-2.5%
|
-6.7%
|
WW
|
|
446
|
|
494
|
-9.6%
|
-3.9%
|
-5.7%
|
ONCOLOGY
|
|
|
|
|
|
|
|
US
|
|
962
|
|
933
|
3.1%
|
3.1%
|
-
|
Intl
|
|
1,556
|
|
1,378
|
13.0%
|
22.2%
|
-9.2%
|
WW
|
|
2,518
|
|
2,311
|
9.0%
|
14.5%
|
-5.5%
|
DARZALEX
|
|
|
|
|
|
|
|
US
|
|
352
|
|
264
|
33.0%
|
33.0%
|
-
|
Intl
|
|
277
|
|
168
|
65.1%
|
80.1%
|
-15.0%
|
WW
|
|
629
|
|
432
|
45.5%
|
51.3%
|
-5.8%
|
IMBRUVICA
|
|
|
|
|
|
|
|
US
|
|
349
|
|
227
|
53.7%
|
53.7%
|
-
|
Intl
|
|
435
|
|
360
|
20.8%
|
32.0%
|
-11.2%
|
WW
|
|
784
|
|
587
|
33.5%
|
40.4%
|
-6.9%
|
VELCADE
|
|
|
|
|
|
|
|
US
|
|
-
|
|
-
|
-
|
-
|
-
|
Intl
|
|
263
|
|
313
|
-16.0%
|
-10.1%
|
-5.9%
|
WW
|
|
263
|
|
313
|
-16.0%
|
-10.1%
|
-5.9%
|
ZYTIGA / Abiraterone
Acetate
|
|
|
|
|
|
|
|
US
|
|
185
|
|
407
|
-54.5%
|
-54.5%
|
-
|
Intl
|
|
494
|
|
438
|
12.9%
|
20.9%
|
-8.0%
|
WW
|
|
679
|
|
845
|
-19.6%
|
-15.4%
|
-4.2%
|
OTHER
ONCOLOGY
|
|
|
|
|
|
|
|
US
|
|
76
|
|
35
|
*
|
*
|
-
|
Intl
|
|
87
|
|
99
|
-12.2%
|
-3.9%
|
-8.3%
|
WW
|
|
163
|
|
134
|
21.7%
|
27.8%
|
-6.1%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
FIRST
QUARTER
|
|
|
|
|
|
%
Change
|
|
|
2019
|
|
2018
|
Reported
|
Operational
(1)
|
Currency
|
PULMONARY
HYPERTENSION
|
|
|
|
|
|
|
|
US
|
|
430
|
|
361
|
19.2%
|
19.2%
|
-
|
Intl
|
|
226
|
|
224
|
0.7%
|
8.6%
|
-7.9%
|
WW
|
|
656
|
|
585
|
12.1%
|
15.1%
|
-3.0%
|
OPSUMIT
|
|
|
|
|
|
|
|
US
|
|
172
|
|
149
|
15.9%
|
15.9%
|
-
|
Intl
|
|
133
|
|
122
|
8.9%
|
17.8%
|
-8.9%
|
WW
|
|
306
|
|
271
|
12.7%
|
16.8%
|
-4.1%
|
TRACLEER
|
|
|
|
|
|
|
|
US
|
|
61
|
|
68
|
-10.1%
|
-10.1%
|
-
|
Intl
|
|
56
|
|
72
|
-22.9%
|
-18.3%
|
-4.6%
|
WW
|
|
117
|
|
140
|
-16.7%
|
-14.4%
|
-2.3%
|
UPTRAVI
|
|
|
|
|
|
|
|
US
|
|
176
|
|
124
|
41.4%
|
41.4%
|
-
|
Intl
|
|
22
|
|
16
|
42.8%
|
53.6%
|
-10.8%
|
WW
|
|
198
|
|
140
|
41.6%
|
42.8%
|
-1.2%
|
OTHER
|
|
|
|
|
|
|
|
US
|
|
21
|
|
20
|
3.6%
|
3.6%
|
-
|
Intl
|
|
15
|
|
14
|
4.6%
|
17.1%
|
-12.5%
|
WW
|
|
35
|
|
34
|
4.0%
|
9.2%
|
-5.2%
|
CARDIOVASCULAR /
METABOLISM / OTHER
|
|
|
|
|
|
|
|
US
|
|
947
|
|
1,103
|
-14.1%
|
-14.1%
|
-
|
Intl
|
|
398
|
|
414
|
-3.9%
|
2.7%
|
-6.6%
|
WW
|
|
1,345
|
|
1,517
|
-11.3%
|
-9.5%
|
-1.8%
|
XARELTO
|
|
|
|
|
|
|
|
US
|
|
542
|
|
578
|
-6.3%
|
-6.3%
|
-
|
Intl
|
|
-
|
|
-
|
-
|
-
|
-
|
WW
|
|
542
|
|
578
|
-6.3%
|
-6.3%
|
-
|
INVOKANA /
INVOKAMET
|
|
|
|
|
|
|
|
US
|
|
154
|
|
204
|
-24.8%
|
-24.8%
|
-
|
Intl
|
|
49
|
|
44
|
11.6%
|
20.0%
|
-8.4%
|
WW
|
|
202
|
|
248
|
-18.4%
|
-16.9%
|
-1.5%
|
PROCRIT /
EPREX
|
|
|
|
|
|
|
|
US
|
|
148
|
|
189
|
-21.6%
|
-21.6%
|
-
|
Intl
|
|
78
|
|
87
|
-10.2%
|
-5.2%
|
-5.0%
|
WW
|
|
226
|
|
276
|
-18.0%
|
-16.4%
|
-1.6%
|
OTHER
|
|
|
|
|
|
|
|
US
|
|
104
|
|
132
|
-21.3%
|
-21.3%
|
-
|
Intl
|
|
271
|
|
283
|
-4.4%
|
2.5%
|
-6.9%
|
WW
|
|
374
|
|
415
|
-9.7%
|
-5.1%
|
-4.6%
|
|
|
|
|
|
|
|
|
TOTAL
PHARMACEUTICAL
|
|
|
|
|
|
|
|
US
|
|
5,582
|
|
5,354
|
4.3%
|
4.3%
|
-
|
Intl
|
|
4,662
|
|
4,490
|
3.9%
|
12.2%
|
-8.3%
|
WW
|
|
$
10,244
|
|
$
9,844
|
4.1%
|
7.9%
|
-3.8%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See footnotes at end
of schedule
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
FIRST
QUARTER
|
|
|
|
|
|
%
Change
|
|
|
2019
|
|
2018
|
Reported
|
Operational
(1)
|
Currency
|
MEDICAL DEVICES
SEGMENT (2)(5)
|
|
|
|
|
|
|
|
DIABETES
CARE(5)
|
|
|
|
|
|
|
|
US
|
|
$
-
|
|
$
117
|
*
|
*
|
-
|
Intl
|
|
-
|
|
222
|
*
|
*
|
*
|
WW
|
|
-
|
|
339
|
*
|
*
|
*
|
INTERVENTIONAL
SOLUTIONS
|
|
|
|
|
|
|
|
US
|
|
343
|
|
304
|
12.6%
|
12.6%
|
-
|
Intl
|
|
389
|
|
336
|
15.8%
|
22.7%
|
-6.9%
|
WW
|
|
732
|
|
640
|
14.3%
|
17.9%
|
-3.6%
|
ORTHOPAEDICS
|
|
|
|
|
|
|
|
US
|
|
1,318
|
|
1,307
|
0.9%
|
0.9%
|
-
|
Intl
|
|
885
|
|
943
|
-6.2%
|
0.7%
|
-6.9%
|
WW
|
|
2,204
|
|
2,250
|
-2.1%
|
0.8%
|
-2.9%
|
HIPS
|
|
|
|
|
|
|
|
US
|
|
213
|
|
209
|
2.1%
|
2.1%
|
-
|
Intl
|
|
148
|
|
154
|
-3.8%
|
3.5%
|
-7.3%
|
WW
|
|
361
|
|
363
|
-0.4%
|
2.7%
|
-3.1%
|
KNEES
|
|
|
|
|
|
|
|
US
|
|
223
|
|
228
|
-2.2%
|
-2.2%
|
-
|
Intl
|
|
146
|
|
159
|
-8.2%
|
-1.5%
|
-6.7%
|
WW
|
|
369
|
|
387
|
-4.7%
|
-1.9%
|
-2.8%
|
TRAUMA
|
|
|
|
|
|
|
|
US
|
|
417
|
|
407
|
2.5%
|
2.5%
|
-
|
Intl
|
|
268
|
|
289
|
-7.0%
|
-0.3%
|
-6.7%
|
WW
|
|
685
|
|
696
|
-1.4%
|
1.3%
|
-2.7%
|
SPINE &
OTHER
|
|
|
|
|
|
|
|
US
|
|
465
|
|
463
|
0.3%
|
0.3%
|
-
|
Intl
|
|
323
|
|
341
|
-5.5%
|
1.3%
|
-6.8%
|
WW
|
|
788
|
|
804
|
-2.2%
|
0.7%
|
-2.9%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
FIRST
QUARTER
|
|
|
|
|
|
%
Change
|
|
|
2019
|
|
2018
|
Reported
|
Operational
(1)
|
Currency
|
SURGERY
|
|
|
|
|
|
|
|
US
|
|
1,001
|
|
993
|
0.8%
|
0.8%
|
-
|
Intl
|
|
1,394
|
|
1,430
|
-2.6%
|
4.7%
|
-7.3%
|
WW
|
|
2,395
|
|
2,423
|
-1.2%
|
3.1%
|
-4.3%
|
ADVANCED
|
|
|
|
|
|
|
|
US
|
|
404
|
|
393
|
2.9%
|
2.9%
|
-
|
Intl
|
|
576
|
|
573
|
0.5%
|
7.7%
|
-7.2%
|
WW
|
|
980
|
|
966
|
1.5%
|
5.8%
|
-4.3%
|
GENERAL
|
|
|
|
|
|
|
|
US
|
|
425
|
|
423
|
0.3%
|
0.3%
|
-
|
Intl
|
|
665
|
|
704
|
-5.6%
|
1.6%
|
-7.2%
|
WW
|
|
1,089
|
|
1,127
|
-3.4%
|
1.1%
|
-4.5%
|
SPECIALTY
|
|
|
|
|
|
|
|
US
|
|
172
|
|
177
|
-2.5%
|
-2.5%
|
-
|
Intl
|
|
153
|
|
153
|
-0.2%
|
7.6%
|
-7.8%
|
WW
|
|
325
|
|
330
|
-1.4%
|
2.2%
|
-3.6%
|
VISION
|
|
|
|
|
|
|
|
US
|
|
446
|
|
440
|
1.5%
|
1.5%
|
-
|
Intl
|
|
682
|
|
675
|
1.1%
|
7.2%
|
-6.1%
|
WW
|
|
1,129
|
|
1,115
|
1.2%
|
5.0%
|
-3.8%
|
CONTACT LENSES /
OTHER
|
|
|
|
|
|
|
|
US
|
|
321
|
|
309
|
4.1%
|
4.1%
|
-
|
Intl
|
|
502
|
|
498
|
1.0%
|
7.4%
|
-6.4%
|
WW
|
|
824
|
|
807
|
2.1%
|
6.1%
|
-4.0%
|
SURGICAL
|
|
|
|
|
|
|
|
US
|
|
125
|
|
131
|
-4.5%
|
-4.5%
|
-
|
Intl
|
|
180
|
|
177
|
1.3%
|
6.8%
|
-5.5%
|
WW
|
|
305
|
|
308
|
-1.1%
|
2.0%
|
-3.1%
|
|
|
|
|
|
|
|
|
TOTAL MEDICAL
DEVICES
|
|
|
|
|
|
|
|
US
|
|
3,109
|
|
3,161
|
-1.6%
|
-1.6%
|
-
|
Intl
|
|
3,350
|
|
3,606
|
-7.1%
|
-0.3%
|
-6.8%
|
WW
|
|
$
6,459
|
|
$
6,767
|
-4.6%
|
-1.0%
|
-3.6%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Note: Columns
and rows within tables may not add due to rounding. Percentages
have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely.
|
|
|
|
|
|
|
|
|
* Percentage greater
than 100% or not meaningful
|
(1) Operational
growth excludes the effect of translational currency
|
(2)
Unaudited
|
(3) Reported as U.S.
sales
|
(4) Prior year
amounts have been reclassified to conform to current year product
disclosure
|
(5) Reflects LifeScan
divestiture October 2, 2018
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/johnson--johnson-reports-2019-first-quarter-results-300832766.html
SOURCE Johnson & Johnson